Home Duke University Press
 QUICK SEARCH:   [advanced]


     
  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


First published on May 23, 2007
A more recent version of this article appeared on July 1, 2007
Neuro Oncol 2007, DOI:10.1215/15228517-2007-015
This Article
Right arrow Advance Publication Full Text (PDF)
Right arrow All Versions of this Article:
9/3/373    most recent
15228517-2007-015v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eichler, A. F.
Right arrow Articles by Henson, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Copyright 2007 by the Society for Neuro-Oncology

Received May 21, 2006
Accepted October 2, 2006

Case Studies

Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate

April F. Eichler 1, Tracy T. Batchelor 1, John W. Henson 2*

1 Pappas Center for Neuro-Oncology and Neurology Service, Massachusetts General Hospital, Boston, MA 02114, and Harvard Medical School, Boston, MA 02115, USA
2 Pappas Center for Neuro-Oncology, Neurology Service, Division of Neuroradiology, and Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, and Harvard Medical School, Boston, MA 02115, USA

* To whom correspondence should be addressed. E-mail: henson{at}helix.mgh.harvard.edu.


   Abstract

Methotrexate (MTX) is a widely used chemotherapeutic agent that can cause acute, subacute, and chronic neurological complications. Subacute MTX neurotoxicity is manifest by abrupt onset of focal cerebral dysfunction occurring days to weeks after MTX administration, usually in children. We describe the neuroimaging features of an adult patient with primary CNS lymphoma who presented with transient aphasia and right hemiparesis 12 days after receiving intravenous high-dose MTX (8 g/m2) chemotherapy. Imaging within 1 h of symptom onset showed bilateral symmetrical restricted diffusion involving white matter of the cerebral hemispheres. CT angiogram and dynamic susceptibility MRI showed no evidence of vasospasm or perfusion defect. MRI five days later showed near-complete resolution of the abnormalities. MRI 31/2 months later showed normal diffusion but new hyperintense T2-weighted signal changes in the subcortical white matter corresponding to previous areas of restricted diffusion. The absence of vascular or perfusion abnormalities suggests that transient cytotoxic edema in white matter may explain the syndrome of subacute MTX neurotoxicity.

Key Words: adult, diffusion, methotrexate, neurotoxicity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





  Home | Help | Feedback | Subscriptions | Archive | Search | Advance Publication


Copyright 2007 by Society for Neuro-Oncology